SEC Company Response from Cellectar Biosciences, Inc. (CLRB) (CIK 0001279704) (CLRB) — Feb 12, 2010
Cellectar Biosciences, Inc. (CLRB) (CIK 0001279704)
Date: Feb. 12, 2010 · CIK: 0001279704 · Accession: 0001144204-10-006981
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-161922
Letter
Unassociated Document
Harry S. Palmin
hpalmin@novelos.com
President and CEO
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
450 Fifth Street, N.W.
Washington, D.C. 20549
February 11, 2010
Re:
Novelos Therapeutics, Inc.
Registration Statement on Form S-1 (File No. 333-161922)
Ladies and Gentlemen:
On February 5, 2010, Novelos Therapeutics, Inc., a Delaware corporation (the “Company”), filed Amendment No. 3 to Registration Statement on Form S-1, File No. 333-161922 (the “Registration Statement”).
Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, the Company hereby requests that the effectiveness of the Registration Statement be accelerated so that the Registration Statement will become effective at 9:00 a.m. EST on Friday, February 12, 2010, or as soon as practicable thereafter.
The Company acknowledges that:
·
should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
·
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
·
the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Please advise Paul Bork of Foley Hoag LLP at 617-832-1113 or, in his absence, Matthew Eckert at 617-832-3057, when the Registration Statement has been declared effective or if the Staff has any questions.
Thank you for your cooperation.
Very
truly yours,
Novelos
Therapeutics, Inc.
Show Raw Text
CORRESP
1
filename1.htm
Unassociated Document
Harry
S. Palmin
hpalmin@novelos.com
President
and CEO
VIA
EDGAR
Securities
and Exchange Commission
Division
of Corporation Finance
450 Fifth
Street, N.W.
Washington,
D.C. 20549
February
11, 2010
Re:
Novelos
Therapeutics, Inc.
Registration Statement on
Form S-1 (File No. 333-161922)
Ladies
and Gentlemen:
On
February 5, 2010, Novelos Therapeutics, Inc., a Delaware corporation (the
“Company”), filed Amendment No. 3 to Registration Statement on Form S-1, File
No. 333-161922 (the “Registration Statement”).
Pursuant
to Rule 461(a) under the Securities Act of 1933, as amended, the Company hereby
requests that the effectiveness of the Registration Statement be accelerated so
that the Registration Statement will become effective at 9:00 a.m. EST on
Friday, February 12, 2010, or as soon as practicable thereafter.
The
Company acknowledges that:
·
should
the Commission or the staff, acting pursuant to delegated authority,
declare the filing effective, it does not foreclose the Commission from
taking any action with respect to the
filing;
·
the
action of the Commission or the staff, acting pursuant to delegated
authority, in declaring the filing effective, does not relieve the Company
from its full responsibility for the adequacy and accuracy of the
disclosure in the filing; and
·
the
Company may not assert staff comments and the declaration of effectiveness
as a defense in any proceeding initiated by the Commission or any person
under the federal securities laws of the United
States.
Please
advise Paul Bork of Foley Hoag LLP at 617-832-1113 or, in his absence, Matthew
Eckert at 617-832-3057, when the Registration Statement has been declared
effective or if the Staff has any questions.
Thank you
for your cooperation.
Very
truly yours,
Novelos
Therapeutics, Inc.
By:
/s/ Harry S. Palmin
Harry
S. Palmin, President and CEO
cc:
Paul
Bork, Esq.
Mr. Jeffrey Riedler
Ms. Laura Crotty
- 2
-